FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213202280> ?p ?o ?g. }

• W3213202280 endingPage "A26" @default.
• W3213202280 startingPage "A25" @default.
• W3213202280 abstract "Background Immune-checkpoint inhibitors (ICIs) revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). 1–3 To date, tissue PD-L1 immunohistochemistry is one of the leading biomarkers for prediction of ICIs response but has several limitations. 4 5 Extracellular vesicles (EVs) are cell-derived structures involved in cell communication and represent a potential minimally invasive alternative to predicting ICI response. 6–9 Based on this and our preliminary results presented at SITC 2020, 10 we hypothesize that EV PD-L1 predicts response to ICIs in NSCLC. Methods This study evaluates an exploratory cohort of advanced/metastatic NSCLC patients receiving ICIs (cohort A) and a validation cohort receiving Pembrolizumab+docetaxel or docetaxel alone (PROLUNG Phase 2 randomized trial) (cohort B). 11 Plasma samples were collected pre-treatment (T1) and at 3 treatment cycles (T2) (figure 1A). Response was assessed by computed-tomography scan at 3 (cohort A) and 6–8 treatment cycles (cohort B) according to mono- or chemotherapy combination therapy. Patients were classified as responders (partial, stable, or complete response) or non-responders (progressive disease) by RECISTv1.1. 12 EVs were isolated by serial ultracentrifugation and characterized following ISEV recommendations. 13,14 Tissue PD-L1 expression was measured by standardized immunohistochemistry (SP263, 22C3, or 28–8 clones) 5 and EV PD-L1 expression by immunoblot and its ratio was calculated as EV PD-L1 T2/T1. Cut-offs from the exploratory cohort were applied to the validation cohort, being EV PD-L1 ratio <0.85 = Low. Results Paired samples from 30 ICIs, 23 pembrolizumab+docetaxel, and 15 docetaxel treated patients were analyzed. In cohort A, non-responders showed higher EV PD-L1 ratio than responders (p=0.012) (figure 1B) with an area-under-the-curve (AUC) of 77.3%, 83.3% sensitivity, and 61.1% specificity, while the tissue PD-L1 was not predictive (AUC=50%). As a validation, pembrolizumab+docetaxel treated non-responders showed higher EV PD-L1 ratio (p=0.036) than responders with an AUC=69.3%, sensitivity=75%, and specificity=63.6%, outperforming the tissue PD-L1 (figure 1C). No statistically significant differences were observed in the docetaxel group (p=0.885). Moreover, ICIs patients with higher EV PD-L1 ratio showed shorter progression-free survival (PFS) (HR=0.30, p=0.066) and overall survival (OS) (HR=0.17, p=0.016) (figure 1D) which was also observed in the pembrolizumab+docetaxel cohort with shorter PFS (HR=0.12, p=0.004) and OS (HR=0.23, p=0.010) (figure 1E). EV PD-L1 ratio did not predict survival in docetaxel-treated patients. Abstract 23 Figure 1 (A) Study design and methodology. (B) EV PD-L1 ratio predicts response to ICIs in 30 NSCLC patients from the discovery cohort A and outperforms tissue PD-L1. (C) EV PD-L1 ratio is predictive for response to pembrolizumab+docetaxel in 23 NSCLC patients but not in 15 patients receiving docetaxel alone from cohort B. (D) Higher EV PD-L1 ratio predicts shorter PFS and OS in 30 patients from the discovery cohort A treated with ICIs. (E) Higher EV PD-L1 ratio is associated with shorter PFS and OS in 23 patients treated with pembrolizumab+docetaxel but not in patients treated with docetaxel alone. Abbreviations: CT: Computed tomography, EV: Extracellular vesicle; HR: Hazard Ratio; ICIs: Immune-checkpoint Inhibitors; IHC: Immunohistochemistry; NR: Non-Responders; OS: Overall Survival; p: p-value; PFS: Progression-free survival; R: Responders [Created with BioRender]. Conclusions We demonstrated that treatment-associated changes in EV PD-L1 levels are predictive of response and survival in advanced NSCLC patients treated with ICIs. This model, if confirmed in a large prospective cohort, could have important clinical implications, guiding treatment decisions and improving the outcome of patients receiving ICIs. Acknowledgements We would like to extend our gratitude to the all the patients that participated in the study. References Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al . Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer. N Engl J Med 2015; 373 :1627–39. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 2016; 387 :1540–50. Ruiz-Patiño A, Arrieta O, Cardona AF, Martín C, Raez LE, Zatarain-Barrón ZL, et al . Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP). Thorac Cancer 2020; 11 :353–61. Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, et al . PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol 2021; 18 :345–362. Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, et al . PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol 2017; 12 :208–222. Poggio M, Hu T, Pai CC, Chu B, Belair CD, Chang A, et al . Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell 2019; 177 :414–427.e13. Cordonnier M, Nardin C, Chanteloup G, Derangere V, Algros MP, Arnould L, et al . Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients. J Extracell Vesicles 2020; 9 :1710899. Del Re M, Cucchiara F, Rofi E, Fontanelli L, Petrini I, Gri N, et al . A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC. Cancer Immunol Immunother 2020; 70 :1667–1678. Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, et al . Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature . 2018;560:382–6. 10 de Miguel Perez D, Russo A, Gunasekaran M, Cardona A, Lapidus R, Cooper B, et al. 31 Dynamic change of PD-L1 expression on extracellular vesicles predicts response to immune-checkpoint inhibitors in non-small cell lung cancer patients. 2020 J Immunother Cancer ; 8 (Suppl 3):A30–A30. Arrieta O, Barrón F, Ramírez-Tirado LA, Zatarain-Barrón ZL, Cardona AF, Díaz-García D, et al. Efficacy and safety of pembrolizumab plus docetaxel vs docetaxel alone in patients with previously treated advanced non–small cell lung cancer: the PROLUNG phase 2 randomized clinical trial. 2020 JAMA Oncol ; 6 :856–864. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). 2009 Eur J Cancer ; 45 :228–47. Reclusa P, Verstraelen P, Taverna S, Gunasekaran M, Pucci M, Pintelon I, et al. Improving extracellular vesicles visualization: From static to motion. 2020 Sci Rep ; 10 :6494. Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. 2018 J Extracell Vesicles ; 7 :1535750 Ethics Approval Patients consented to Institutional Review Board–approved protocol, A.O. Pappardo, Messina, Italy for cohort A and Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), México City, México in case of the cohort B. Biological material was transferred to the University of Maryland School of Medicine, Baltimore for EV analysis under signed MTA between institutions MTA/2020–13111 & MTA/2020–13113." @default.
• W3213202280 created "2021-11-22" @default.
• W3213202280 creator A5005436649 @default.
• W3213202280 creator A5007170973 @default.
• W3213202280 creator A5008894786 @default.
• W3213202280 creator A5010265482 @default.
• W3213202280 creator A5012141584 @default.
• W3213202280 creator A5020080512 @default.
• W3213202280 creator A5025014274 @default.
• W3213202280 creator A5029741791 @default.
• W3213202280 creator A5035063101 @default.
• W3213202280 creator A5054443196 @default.
• W3213202280 creator A5071851332 @default.
• W3213202280 creator A5074506844 @default.
• W3213202280 creator A5087117639 @default.
• W3213202280 creator A5090179091 @default.
• W3213202280 date "2021-11-01" @default.
• W3213202280 modified "2023-10-14" @default.
• W3213202280 title "23 Validation of PD-L1 dynamic expression on extracellular vesicles as a predictor of response to immune-checkpoint inhibitors and survival in non-small cell lung cancer patients" @default.
• W3213202280 cites W2104347254 @default.
• W3213202280 cites W2198093519 @default.
• W3213202280 cites W2887249435 @default.
• W3213202280 cites W2934922729 @default.
• W3213202280 cites W2999741543 @default.
• W3213202280 cites W3015756332 @default.
• W3213202280 cites W3099502788 @default.
• W3213202280 cites W3111799242 @default.
• W3213202280 doi "https://doi.org/10.1136/jitc-2021-sitc2021.023" @default.
• W3213202280 hasPublicationYear "2021" @default.
• W3213202280 type Work @default.
• W3213202280 sameAs 3213202280 @default.
• W3213202280 citedByCount "0" @default.
• W3213202280 crossrefType "journal-article" @default.
• W3213202280 hasAuthorship W3213202280A5005436649 @default.
• W3213202280 hasAuthorship W3213202280A5007170973 @default.
• W3213202280 hasAuthorship W3213202280A5008894786 @default.
• W3213202280 hasAuthorship W3213202280A5010265482 @default.
• W3213202280 hasAuthorship W3213202280A5012141584 @default.
• W3213202280 hasAuthorship W3213202280A5020080512 @default.
• W3213202280 hasAuthorship W3213202280A5025014274 @default.
• W3213202280 hasAuthorship W3213202280A5029741791 @default.
• W3213202280 hasAuthorship W3213202280A5035063101 @default.
• W3213202280 hasAuthorship W3213202280A5054443196 @default.
• W3213202280 hasAuthorship W3213202280A5071851332 @default.
• W3213202280 hasAuthorship W3213202280A5074506844 @default.
• W3213202280 hasAuthorship W3213202280A5087117639 @default.
• W3213202280 hasAuthorship W3213202280A5090179091 @default.
• W3213202280 hasBestOaLocation W32132022801 @default.
• W3213202280 hasConcept C143998085 @default.
• W3213202280 hasConcept C203014093 @default.
• W3213202280 hasConcept C2776256026 @default.
• W3213202280 hasConcept C2777701055 @default.
• W3213202280 hasConcept C2780851360 @default.
• W3213202280 hasConcept C2781053074 @default.
• W3213202280 hasConcept C28406088 @default.
• W3213202280 hasConcept C2992929900 @default.
• W3213202280 hasConcept C502942594 @default.
• W3213202280 hasConcept C71924100 @default.
• W3213202280 hasConcept C86803240 @default.
• W3213202280 hasConcept C8891405 @default.
• W3213202280 hasConcept C95444343 @default.
• W3213202280 hasConceptScore W3213202280C143998085 @default.
• W3213202280 hasConceptScore W3213202280C203014093 @default.
• W3213202280 hasConceptScore W3213202280C2776256026 @default.
• W3213202280 hasConceptScore W3213202280C2777701055 @default.
• W3213202280 hasConceptScore W3213202280C2780851360 @default.
• W3213202280 hasConceptScore W3213202280C2781053074 @default.
• W3213202280 hasConceptScore W3213202280C28406088 @default.
• W3213202280 hasConceptScore W3213202280C2992929900 @default.
• W3213202280 hasConceptScore W3213202280C502942594 @default.
• W3213202280 hasConceptScore W3213202280C71924100 @default.
• W3213202280 hasConceptScore W3213202280C86803240 @default.
• W3213202280 hasConceptScore W3213202280C8891405 @default.
• W3213202280 hasConceptScore W3213202280C95444343 @default.
• W3213202280 hasIssue "Suppl 2" @default.
• W3213202280 hasLocation W32132022801 @default.
• W3213202280 hasLocation W32132022802 @default.
• W3213202280 hasOpenAccess W3213202280 @default.
• W3213202280 hasPrimaryLocation W32132022801 @default.
• W3213202280 hasRelatedWork W1533135684 @default.
• W3213202280 hasRelatedWork W2318567272 @default.
• W3213202280 hasRelatedWork W2786497694 @default.
• W3213202280 hasRelatedWork W2907279061 @default.
• W3213202280 hasRelatedWork W2980533584 @default.
• W3213202280 hasRelatedWork W3176297088 @default.
• W3213202280 hasRelatedWork W3215044659 @default.
• W3213202280 hasRelatedWork W3217115064 @default.
• W3213202280 hasRelatedWork W4323664831 @default.
• W3213202280 hasRelatedWork W2553145634 @default.
• W3213202280 hasVolume "9" @default.
• W3213202280 isParatext "false" @default.
• W3213202280 isRetracted "false" @default.
• W3213202280 magId "3213202280" @default.
• W3213202280 workType "article" @default.